Literature DB >> 1336458

Characterization of a biologically active extracellular domain of fibroblast growth factor receptor 1 expressed in Escherichia coli.

L Bergonzoni1, P Caccia, O Cletini, P Sarmientos, A Isacchi.   

Abstract

The functional features of a recombinant fibroblast growth factor (FGF) receptor (FGF-R) were investigated by expressing at high level in Escherichia coli a soluble non-glycosylated form of FGF-R1. The extracellular domain of the mature protein (XC-FGF-R), comprising the first 356 amino acids, was purified from a large-scale fermentation. After cell lysis, the protein was quantitatively found in the pellet. XC-FGF-R was solubilized using guanidine/HCl and allowed to refold using two dialysis steps. The refolded protein was obtained in a homogeneous form after ammonium sulphate precipitation and gel-filtration chromatography. The soluble receptor had the ability to form a complex with recombinant human basic FGF (rhbFGF) in solution, as demonstrated by immunoprecipitation with anti-(FGF-R) serum. Formation of a rhbFGF/XC-FGF-R complex was visualized by cross-linking experiments. Quantitative binding experiments with the XC-FGF-R immobilized on Affi-Gel resin showed high binding affinity for 125I-bFGF (Kd = 5-10 nM). Purified XC-FGF-R inhibited binding of 125I-bFGF to its high-affinity receptors on baby hamster kidney cells. These data suggest that glycosylation of the FGF-R is not necessary for its ligand-binding activity. The use of an E. coli expression system resulted in the efficient production of a soluble receptor in a form suitable for ligand/receptor structural studies and screening of new potential agonists and antagonists of angiogenesis. These results indicate that E. coli can be used for the production of complex molecules such as Ig-like receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336458     DOI: 10.1111/j.1432-1033.1992.tb17485.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Nuclear accumulation of fibroblast growth factor receptors is regulated by multiple signals in adrenal medullary cells.

Authors:  M K Stachowiak; P A Maher; A Joy; E Mordechai; E K Stachowiak
Journal:  Mol Biol Cell       Date:  1996-08       Impact factor: 4.138

2.  A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells.

Authors:  M Rusnati; P Dell'Era; C Urbinati; E Tanghetti; M L Massardi; Y Nagamine; E Monti; M Presta
Journal:  Mol Biol Cell       Date:  1996-03       Impact factor: 4.138

3.  Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures.

Authors:  M Rusnati; E Tanghetti; C Urbinati; G Tulipano; S Marchesini; M Ziche; M Presta
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

4.  Fibroblast growth factor (FGF) soluble receptor 1 acts as a natural inhibitor of FGF2 neurotrophic activity during retinal degeneration.

Authors:  X Guillonneau; F Régnier-Ricard; O Laplace; L Jonet; M Bryckaert; Y Courtois; F Mascarelli
Journal:  Mol Biol Cell       Date:  1998-10       Impact factor: 4.138

5.  Biochemical characterization of the molecular interaction between recombinant basic fibroblast growth factor and a recombinant soluble fibroblast growth factor receptor.

Authors:  P Caccia; O Cletini; A Isacchi; L Bergonzoni; G Orsini
Journal:  Biochem J       Date:  1993-09-15       Impact factor: 3.857

6.  Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican.

Authors:  R Steinfeld; H Van Den Berghe; G David
Journal:  J Cell Biol       Date:  1996-04       Impact factor: 10.539

Review 7.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.